​

MBX Biosciences (MBX) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChart

MBX Stock Forecast


MBX Biosciences (MBX) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $97.67, with a high of $150.00 and a low of $84.00. This represents a 83.94% increase from the last price of $53.10.

- $30 $60 $90 $120 $150 High: $150 Avg: $97.67 Low: $84 Last Closed Price: $53.1

MBX Stock Rating


MBX Biosciences stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

MBX Price Target Upside V Benchmarks


TypeNameUpside
StockMBX Biosciences83.94%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends


1M3M12M
# Anlaysts1315
Avg Price Target$86.00$106.67$74.27
Last Closing Price$53.10$53.10$53.10
Upside/Downside61.96%100.89%39.87%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 2638---11
Oct, 2638---11
Sep, 2639---12
Aug, 2629---11
Jul, 2629-1-12
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 27, 2026Jonathan WollebenCitizens$86.00$52.9762.36%61.96%
Oct 12, 2026Annabel SamimyStifel Nicolaus$84.00$53.2457.78%58.19%
Oct 02, 2026Seamus FernandezGuggenheim$150.00$56.55165.25%182.49%
Aug 10, 2026Truist Financial$88.00$65.8733.60%65.73%
Aug 07, 2026Barclays$88.00$67.1131.13%65.73%
Jul 23, 2026Michael YeeUBS$90.00$61.8445.54%69.49%
May 12, 2026Stifel Nicolaus$56.00$38.9943.63%5.46%
May 12, 2026Barclays$70.00$40.0874.65%31.83%
May 11, 2026Srikripa DevarakondaTruist Financial$70.00$43.7959.85%31.83%
Mar 09, 2026Srikripa DevarakondaTruist Financial$50.00$28.7873.73%-5.84%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Nov 12, 2026H.C. WainwrightBuyinitialise
Oct 27, 2026CitigroupMarket OutperformMarket Outperformhold
Oct 02, 2026GuggenheimBuyBuyhold
Sep 28, 2026UBSBuyBuyhold
Aug 07, 2026BarclaysOverweightOverweighthold
Jul 23, 2026UBSBuyBuyhold
May 12, 2026BarclaysOverweightOverweighthold
May 12, 2026CitigroupOutperformOutperformhold
Mar 12, 2026Cowen & Co.BuyBuyhold
Feb 24, 2026UBSBuyBuyhold

Financial Forecast


EPS Forecast

$-25 $-20 $-15 $-10 $-5 $0 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-1.85$-2.38----
Avg Forecast$-11.52$-2.82$-2.76$-3.45$-2.95$-2.77
High Forecast$-5.28$-2.44$-2.25$-3.22$-2.95$-2.77
Low Forecast$-23.87$-3.11$-3.08$-3.69$-2.95$-2.77
Surprise %-83.94%-15.60%----

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported------
Avg Forecast-----$44.05M
High Forecast-----$44.05M
Low Forecast-----$44.05M
Surprise %------

Net Income Forecast

$-800M $-650M $-500M $-350M $-200M $-50M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-61.92M$-86.97M----
Avg Forecast$-486.68M$-102.04M$-89.01M$-115.46M$-98.51M$-92.50M
High Forecast$-176.21M$-81.59M$-75.30M$-107.56M$-98.51M$-92.50M
Low Forecast$-797.16M$-103.73M$-102.71M$-123.35M$-98.51M$-92.50M
Surprise %-87.28%-14.77%----

MBX Forecast FAQ


Is MBX Biosciences stock a buy?

MBX Biosciences stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that MBX Biosciences is a favorable investment for most analysts.

What is MBX Biosciences's price target?

MBX Biosciences's price target, set by 7 Wall Street analysts, averages $97.67 over the next 12 months. The price target range spans from $84 at the low end to $150 at the high end, suggesting a potential 83.94% change from the previous closing price of $53.1.

How does MBX Biosciences stock forecast compare to its benchmarks?

MBX Biosciences's stock forecast shows a 83.94% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for MBX Biosciences over the past three months?

  • November 2026: 27.27% Strong Buy, 72.73% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2026: 27.27% Strong Buy, 72.73% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is MBX Biosciences’s EPS forecast?

MBX Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.76, marking a 15.97% increase from the reported $-2.38 in 2025. Estimates for the following years are $-3.45 in 2027, $-2.95 in 2028, and $-2.77 in 2029.

What is MBX Biosciences’s revenue forecast?

MBX Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $0, followed by $0 for 2028, and $44.05M for 2029.

What is MBX Biosciences’s net income forecast?

MBX Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $-89.007M, representing an 2.34% increase from the reported $-86.971M in 2025. Projections indicate $-115M in 2027, $-98.508M in 2028, and $-92.498M in 2029.